News
Market and company headlines
RMDAll
Loading
07:00Oct 231 Story
09:00-23:00Oct 222 Stories
Learn Why The Bull Case For ResMed (RMD) Could Change Following U.S. Mask Launch
ResMed has launched the AirTouch F40 CPAP mask in the U.S., a fabric-cushioned, minimalist design that connects into its myAir and AirView platforms and is intended to support comfort, adherence and easier fitting for obstructive sleep apnea patients. The ability for existing AirFit F40 users to switch to the new ComfiSoft fabric cushion without a full refit highlights how ResMed is trying to lift adherence and resupply activity while keeping patients inside its connected ecosystem. We will...
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
08:00Oct 191 Story
00:00Oct 151 Story
03:00Oct 121 Story
08:00-13:00Oct 72 Stories
Wednesday's session: top gainers and losers in the S&P500 index
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.
07:00Oct 71 Story
12:00Oct 51 Story
06:00-17:00Oct 12 Stories
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: https://investor.resmed.comDate
Top 25 High-Growth Dividend Stocks For October 2026
October 2026 Top 25 High-Growth Dividend Stocks trading 31% below intrinsic value, with a projected 22.53% annual return. Read full analysis here.
16:00Sep 281 Story
04:00Sep 191 Story
15:00-17:00Sep 152 Stories
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price target to $262 from $244, citing growing demand for sleep apnea devices. The firm said that ResMed a top provider of devices for respiratory care and obstructive sleep apnea (OSA), is poised to gain market share as global awareness of the condition grows.
This Analyst Just Upgraded ResMed Stock. Here's Why.
ResMed stock rallies on a bullish RBC Capital research note. Here’s why analyst Craig Wong-Pan raised his price target on RMD shares today.
13:00-15:00Sep 152 Stories
RBC Capital Upgrades ResMed to Outperform from Sector Perform
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply chain costs. Although the wider patient monitoring sector generally outperformed expectations, ResMed delivered the weakest revenue surprise and slowest growth among peers, raising questions about how rising expenses could affect its profitability...
10:00-12:00Sep 152 Stories
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
06:00-00:00Aug 192 Stories
Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
16:00-18:00Aug 172 Stories
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Nominating and Governance Chair Carol Burt to become Lead Director.Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelec
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]
09:00Aug 151 Story
06:00Aug 121 Story
12:00-23:00Aug 113 Stories
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?
In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
01:00-08:00Aug 102 Stories
Resmed’s stock falls by 7% on soft FY27 outlook
Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.